WHAT IS CLAIMED IS:

1. Use of (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and metformin for manufacturing a medicament for combination therapy of diabetes mellitus.

2. The use of claim 1, wherein the (R)-(+)-verapamil or the pharmaceutically acceptable salt thereof is in crystalline form.

3. The use of claim 2, wherein the (R)-(+)-verapamil exist in its hydrochloride salt.

4. The use of claim 1, wherein the medicament is suitable for oral, intraveneous, intramuscular, subcutaneous, transmucosal, or intrarectal administration.

5. The use of claim 1, wherein the medicament for oral administration is provided as tablets, pills, granules, powders, solutions, suspensions, syrups or capsules.

6. The use of claim 1, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered in the amount of 15 to 1,000 mg/day.

7. The use of claim 6, wherein the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof is administered in the amount of 25 to 800 mg/day.

8. The use of claim 1, wherein the combination therapy comprises administering the (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and the metformin independently.